271. 強直性脊椎炎 Ankylosing spondylitis Clinical trials / Disease details

臨床試験数 : 563 /  薬物数 : 372 - (DrugBank : 72) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 145

  
11 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1ChiCTR2100044284
2021-03-092021-03-14Study on the effect of ginger with different thickness on the treatment of ankylosing spondylitisEffect of Fuyang and Dumoxibustion on Ankylosing Spondylitis of Kidney-Yang Deficiency and on TNF-a and IL-6 Ankylosing spondylitisThe control group:Celecoxib 20mg once daily;Ginger tube moxibustion group:Oral celecoxib 20mg once a day, combined with Du moxibustion (ginger thickness 3cm);Thick ginger du moxibustion group:Oral celecoxib 20mg once a day, combined with Du moxibustion (ginger 5cm thickness);Affiliated Hospital of Nanjing University of Chinese MedicineNULLRecruiting1860MaleThe control group:20;Ginger tube moxibustion group:20;Thick ginger du moxibustion group:20;China
2ChiCTR2100042789
2021-02-012021-01-28Clinical Study on the Treatment of Ankylosing Spondylitis with Integrated Traditional Chinese and Western MedicineClinical Study on the Treatment of Ankylosing Spondylitis with Integrated Traditional Chinese and Western Medicine Ankylosing Spondylitisintegrated traditional Chinese and western medicine:Bushen-Qiangdu-Zhilv decoction and Celecoxib Capsules;Guangdong Provincial Hospital of Chinese MedicineNULLRecruiting1870Bothintegrated traditional Chinese and western medicine:27;China
3ChiCTR2000034142
2019-04-012020-06-26Study on TCM Syndrome Classification and Diagnosis and Treatment of Ankylosing Spondylitis by MetabolomicsStudy on TCM Syndrome Classification and Diagnosis and Treatment of Ankylosing Spondylitis by Metabolomics Ankylosing spondylitisExperimental group:Take Chinese medicine preparation Wen-Shen Juan-Bi-Tang orally;Experimental group 2:Take Chinese medicine preparation modified Wen-Shen Juan-Bi-Tang orally;NSAID:Take celecoxib orally;Jiangsu Province Hospital of TCMNULLPending2570BothExperimental group:40;Experimental group 2:40;NSAID:40;N/AChina
4NCT03473665
(ClinicalTrials.gov)		March 1, 201813/3/2018Non-Steroidal Anti-inflammatory Drugs in Axial SpondyloarthritisNon-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot StudyAnkylosing Spondylitis;Axial SpondyloarthritisDrug: Indomethacin;Drug: Diclofenac;Drug: Meloxicam;Drug: CelecoxibColumbia UniversityNULLTerminated18 YearsN/AAll9Phase 4United States
5NCT02758782
(ClinicalTrials.gov)		September 201620/4/2016NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing SpondylitisCOmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre TrialAnkylosing SpondylitisBiological: Golimumab;Drug: CelecoxibCharite University, Berlin, GermanyNULLCompleted18 YearsN/AAll156Phase 4Germany
6NCT02638896
(ClinicalTrials.gov)		January 201620/12/2015Dose Reduction of Etanercept in Patients With Ankylosing SpondylitisEfficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing SpondylitisAnkylosing SpondylitisDrug: etanercept (Half-Dose);Drug: etanercept (Full-Dose);Drug: Sulfasalazine;Drug: CelecoxibZhixiang HuangNULLNot yet recruiting18 Years45 YearsBoth100Phase 4NULL
7NCT01934933
(ClinicalTrials.gov)		September 24, 201417/8/2013Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing SpondylitisA Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing SpondylitisAnkylosing SpondylitisDrug: celebrex;Drug: Enbrel;Drug: Enbrel plus CelebrexSun Yat-sen UniversityNULLCompleted18 Years65 YearsAll150Phase 4China
8NCT01709656
(ClinicalTrials.gov)		March 201210/10/2012A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing SpondylitisA Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing SpondylitisAnkylosing SpondylitisBiological: MSC;Drug: celecoxib, Celebrex®Sun Yat-sen UniversityNULLCompleted16 Years65 YearsBoth120N/AChina
9NCT00762463
(ClinicalTrials.gov)		July 200929/9/2008Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing SpondylitisA 6-Week, Randomized, Double-Blind, Parallel-Group Study To Evaluate The Symptomatic Effects And Safety Of Celecoxib 200mg QD Compared To Diclofenac 75mg SR QD In Chinese Patients With Ankylosing Spondylitis, With 6-Week Extension Phase Treatment On Celecoxib 400 Mg QD Or Maintaining Double-Blind Phase TherapyAnkylosing SpondylitisDrug: Celecoxib;Drug: Diclofenac SRPfizer's Upjohn has merged with Mylan to form Viatris Inc.NULLCompleted18 Years65 YearsAll240Phase 3China
10NCT00648141
(ClinicalTrials.gov)		January 200328/3/2008Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing SpondylitisA 12-Week Symptomatic Effect Evaluation to Compare Celecoxib 200 mg QD, Celecoxib 200 mg BID and Diclofenac 75 mg SR BID in Patients With Ankylosing SpondylitisSpondylitis, AnkylosingDrug: Celecoxib;Drug: DiclofenacPfizerNULLCompleted18 Years75 YearsBoth458Phase 3Germany
11NCT02528201
(ClinicalTrials.gov)		September 200218/6/2015A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing SpondylitisA Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing SpondylitisAnkylosing SpondylitisDrug: Celecoxib 200 milligrams;Drug: Celecoxib 400 milligrams;Drug: diclofenac 50 milligramsPfizerNULLCompleted18 Years75 YearsBoth330Phase 4Norway

先頭へ